Remdesivir, an antiviral drug that has not yet been formally approved since the outbreak, has attracted much attention, and clinical “cases” have been fueling hope.
On March 30, local time, researchers at the University of California, Davis published a report entitled “A Transmitted Case” in the journal Clinical Infectious Diseases, a leading international journal on infectious diseases. A paper by Acute Acute De A De to SARS CoV2 in The United States shows that health care providers are once again using Ridsewe to effectively treat a critically ill patient with new coronary pneumonia.
This is the second publicly disclosed success case of a new coronavirus treated with Redcivir, following a detailed account of the first case of new coronavirus infection in the United States in the New England Journal of Medicine (NEJM). The study”, “First Case of 2019 Novel Coronavirus in The United States,” was published online on January 31 in the New England Journal of Medicine. The paper describes the epidemiological and clinical characteristics of the first confirmed case of new coronavirus infection in the United States. The patient initially had mild symptoms and progressed to pneumonia on the ninth day of the disease, followed by the as-yet-approved drug Ridsiewe, which showed that the treatment was effective.
Despite the good results, the team stressed that it was not clear whether Redsiewe was effective for human COVID-19. Large-scale clinical trials are the key to analyzing the drug’s efficacy against new coronary pneumonia.
The authors of the paper are Angela Haczku and Michael Schivo, experts in the Department of Pulmonary, Intensive Care and Sleep Medicine at the University of California, Davis School of Medicine, and Stuart Cohen, director of the Department of Infectious Diseases and Director of Epidemiology and Infection Control at the University of California, Davis School of Medicine.
As of March 30, the virus had infected more than 750,000 people worldwide and killed more than 36,000 people. As a result, teams from many countries are working on treatment options.
Redciewe was originally developed by Gilead in the United States to fight the Ebola virus experimental drug, it inhibits the replication of the virus by inhibiting RNA-dependent RNA polymerase (RdRP). However, in previous trials of Ebola virus treatment, Redciewe therapy failed due to a high mortality rate of 53% (93/175).
Redsey’s molecular structure
However, several studies have found that Redcivir can effectively reduce lung virus load in mouse models of SARS-CoV (Severe Acute Respiratory Syndrome Coronary Virus) and has effective antiviral activity for new coronaviruses (SARS-CoV-2). There have been several reports of severe new crown patients having significantly improved their condition after receiving ridsiewe.
In several human cell lines, Redcievir has been found to be effective in metabolizing as active nucleoside triphosphate. An in vitro study showed that nucleoside triphosphate competes with adenosine triphosphate to interfere with the virus’s RdRp, similar to playing the role of a delayed RNA chain termination sub, avoiding the correction of extra-viral RNA, and leading to a decrease in viral RNA production.
In addition, a recent cell culture study has shown that the drug inhibits the new coronavirus in the African Green Monkey Kidney Cells (Vero E6 cells).
As a result, Redciewe’s clinical use in COVID-19 cases is highly anticipated and is considered to be the most promising drug to cure new coronary pneumonia. The World Health Organization (WHO) recently listed it as the top of four of the most promising treatments for new coronary pneumonia.
Redsey weer re”s”
The patient, a woman in her 40s, was in good health before the infection, was hospitalized with a respiratory infection and chest CT imaging showed acquired pneumonia, the team from the University of California, Davis said in a report. The hospital immediately quarantined it to prevent the spread of the infection.
Within 24 hours of her admission, her breathing condition worsened. The hospital administered her tubes and gave her antibiotics, including linamolamine, pyrazole-tamataman and azithromycin.
The team at the University of California, Davis, suspected the patient of a potential COVID-19 infection. However, because the patient has not been to a high-risk country and has not been in contact with a high-risk person, she does not meet CDC standards. Therefore, no new coronavirus tests have been performed.
Subsequently, the patient developed acute respiratory distress syndrome (ARDS) and septic shock, because of her severe respiratory condition, the CDC recommended a new coronavirus nucleic acid test, testing positive for the new coronavirus.
Because of the patient’s serious illness, the treatment team obtained a special approval from the U.S. Food and Drug Administration (FDA) to use Redcivir for treatment.
Patient chest CT test results
After the patient was treated with Rhedcive, the patient’s condition improved, reduced the need for ventilator support, blood oxygen levels and chest CT test results improved. After 14 days of hospitalization, mechanical ventilation has been evacuated. The patient has been discharged from hospital and is recovering at home.
The team stressed that it was not clear whether Redsiewe was effective against human COVID-19. Large-scale clinical trials are the key to analyzing the drug’s efficacy against new coronary pneumonia.
Phase III experiment was unveiled at the end of April
Redsieway has been approved for Phase III clinical trials in several countries around the world, and in China, the experiment is being led by Professor Cao Bin of the China-Japan Friendship Hospital in Beijing. It is reported that the experiment began on February 3 and is expected to end on April 27. The trial was a randomized, double-blind, placebo-controlled multicenter clinical study with an estimated sample size of 270, including patients with mild and moderate new coronary pneumonia.
Earlier, on January 31st, the New England Journal of Medicine published online about the clinical symptoms and treatment of the first confirmed case of new coronary pneumonia in the United States. The study noted that patients received injection syrapy treatment for Ridsiewe after the condition worsened, and the symptoms improved significantly the next day.
NEJM study on first confirmed new coronain in the United States
It is reported that the 5th day of the patient’s hospitalization, that is, the 9th day after the onset of symptoms, the lower left lung has pneumonia characteristics, breathing conditions have also worsened.
On the seventh night of his hospitalization, the patient received an intravenous infusion of Ridsiewe.
On the second day of infusion, the patient’s clinical symptoms improved: the patient no longer needed oxygen absorption, oxygen saturation was restored to 94% to 96%, and the initial double-sided lower leaf hearing sound was no longer present. The patient’s appetite also improved, with no symptoms other than intermittent dry coughs and runny noses.
On February 15th the Hospital of the Bordeaux Medical College (CHU) in France also announced that a 48-year-old Chinese man had been cured by a 10-day reedcivee intravenous injection. The case has not yet been reported in detail.
“This antiviral drug responds directly to the virus, spreading perfectly through the lungs of the disease and preventing the spread of the virus,” the hospital’s doctors said. “
In a review of Ridsiewe drugs published by a team of teams such as Taiwan Success University in Taiwan, Taoyuan Branch of Changyu Hospital in Taiwan, and Aix-Marseille University in France in the international mainstream journal journal Journal of Antimicrobial Research in the United Kingdom, The researchers believe that Redciewe, who has not yet been approved for listing, has shown hope in treating COVID-19 and deserves “high expectations.”